



Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

October 21, 2024 at 7:01 AM EDT

DURHAM, N.C.--(BUSINESS WIRE)--Oct. 21, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences.

Longwood Boston CEO Conference

Date: Monday, October 28, 2024

Time: 11:10 AM ET

Title: Expanding Platform Potential

Format: Panel

Guggenheim Inaugural Healthcare Conference

Date: Monday, November 11, 2024

Time: 3:00 PM ET

Location: InterContinental Boston

Format: Fireside Chat

Webcast Link: [Register Here](#)

A live webcast for the Guggenheim Inaugural Healthcare Conference will also be accessible on Precision's website in the Investors section under Events & Presentations at investor.precisionbiosciences.com. An archived replay of the webcasts will be available for approximately 30 days following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20241021549147/en/): <https://www.businesswire.com/news/home/20241021549147/en/>

Investor and Media Contact:

Naresh Tanna

Vice President of Investor Relations

naresh.tanna@precisionbiosciences.com

Source: Precision BioSciences, Inc.